The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Share Option Scheme and Grant to PDMR

4 Dec 2017 07:00

RNS Number : 2141Y
Cronin Group PLC
04 December 2017
 

4 December 2017

Cronin Group Plc

("Cronin" or the "Company")

Adoption of New Share Option Scheme

and

Grant of Options to a PDMR

 

Cronin Group Plc, the AIM listed company focusing on digitizing chemistry, announces the adoption of the Cronin Group Plc Share Option Plan 2017 (the "Plan") and the grant of options to all employees of its subsidiary, Cronin 3D Limited, including a person discharging managerial responsibilities ("PDMR").

 

The Plan is being introduced to recruit, retain and incentivise Directors and employees of the Company and its subsidiaries (the "Group"). The number of options that may be awarded under the Plan is limited to a maximum number of new ordinary shares of 0.01p each in the Company ("Ordinary Shares") representing 11 per cent. of the Company's issued share capital, and may be issued as tax-effective enterprise management incentives where appropriate.

The Board has approved the terms of the Plan and, authorised an initial award of options to employees on 1 December 2017 (the "Date of Grant") over 1,936,667 Ordinary Shares at an exercise price of 2.13p (being the closing price on 30 November 2017, the business day preceding the Date of Grant). The award represents approximately 0.35 per cent. of the Company's issued share capital.

Of the 1,936,667 options granted under the Plan, 677,871 vest on the date of grant. The balance vest in monthly instalments until either three years from the Date of Grant, or in the case of certain longer serving employees, from the earlier date of three years from the end of each of the employees' respective historic probation periods. The options are all exercisable for 10 years from the Date of Grant and the Plan will expire on 30 November 2027.

Within the award of options referred to above, Steve Coles, the Company's Chief Technology Officer, who is identified as a PDMR, has been granted options over a total of 1,666,667 Ordinary Shares, of which 648,148 vest on the Date of Grant and vesting of the balance is in monthly instalments thereafter until 1 October 2019.

 

For further information:

Cronin Group Plc

www.croningroupplc.com

Mark Warne, Executive Chairman

T: 0141 465 6871

Stockdale Securities Limited

T: 020 7601 6100

Tom Griffiths/Edward Thomas

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHKMMGZRMGGNZM
Date   Source Headline
5th Jan 20237:00 amRNSCancellation - DEEPMATTER GROUP PLC
4th Jan 20238:00 amRNSHolding(s) in Company
29th Dec 20225:30 pmRNSDeepmatter Group
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
19th Dec 20223:44 pmRNSResult of General Meeting
19th Dec 20222:05 pmRNSSecond Price Monitoring Extn
19th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 202211:05 amRNSSecond Price Monitoring Extn
19th Dec 202211:00 amRNSPrice Monitoring Extension
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:05 pmRNSSecond Price Monitoring Extn
15th Dec 20222:00 pmRNSPrice Monitoring Extension
9th Dec 202211:05 amRNSSecond Price Monitoring Extn
9th Dec 202211:00 amRNSPrice Monitoring Extension
8th Dec 20228:46 amRNSHolding(s) in Company
2nd Dec 20227:00 amRNSPosting of Circular
1st Dec 20227:00 amRNSProposed Cancellation of Ordinary Shares
24th Nov 20227:00 amRNSCorporate Update
31st Oct 202212:00 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading Update
26th Oct 20227:00 amRNSDeepMatter signs multi-year license agreement
26th Aug 20221:25 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHalf Year Results
28th Jun 20227:00 amRNSDeepMatter acquires AI specialist ChemIntelligence
20th Jun 20224:41 pmRNSSecond Price Monitoring Extn
20th Jun 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20222:05 pmRNSSecond Price Monitoring Extn
20th Jun 20222:00 pmRNSPrice Monitoring Extension
20th Jun 202211:05 amRNSSecond Price Monitoring Extn
20th Jun 202211:00 amRNSPrice Monitoring Extension
9th Jun 20225:26 pmRNSHolding(s) in Company
27th May 20222:30 pmRNSResult of AGM
25th May 20222:30 pmRNSIssue of Equity and TVR
23rd May 20227:00 amRNSDirectorate Change
20th May 20227:00 amRNSContract extension
11th May 20227:00 amRNSContract
27th Apr 20227:00 amRNSFinal Results
30th Mar 20224:00 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSContract
14th Feb 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20223:20 pmRNSHolding(s) in Company
26th Jan 20223:15 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 202212:30 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSDirector/PDMR Shareholding
25th Jan 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.